



HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.

(A Govt. of Maharashtra Undertaking)

Regd. office- Acharya Donde Marg, Parel, Mumbai-400012

Phone: +91-22-24129320-22/24147564

Email:md@vaccinehaffkine.com

EOI No. HBPCL/EOI/001/DPT/2026

Invitation for Expression of Interest (EOI)

For

**Joint Venture / Strategic partnership of
(Development of Vaccine for DPT, TT, or Pentavalent)**

By

Haffkine Bio Pharmaceutical Corporation Ltd.

(A Govt. of Maharashtra Undertaking)

Regd. Office- Acharya Donde Marg, Parel, Mumbai-400012

Phone: +91-22-24129320-22/24147564

CONTENTS

Sl. No	Section	Page No.
1	Letter of Invitation	3
2	Objective	4
3	Scope of Work	4
4	Intellectual Property Rights	5
5	Process involved in Partnership/Collaboration/Technology Transfer	6
6	Security Deposit	6
7	Details of documents to be furnished	7
8	Rejection Criteria	7
9	Evaluation Methodology	7
10	Pre-Qualification Criteria (PQC)	8
11	Disclaimer	9
12	Arbitration	9
13	Expression of Interest (Format – 1)	10
14	Authorization Letter (Format – 2)	12
15	Undertaking with regard to Blacklisting (Format-3)	13
16	Undertaking with regard to Non-Conviction (Format – 4)	14
17	Undertaking with regard to laboratory facility (Format – 5)	15
18	Production Capacity Undertaking (Format-6)	16

Letter of Invitation

1. Invitation for Expression of Interest /

Haffkine Bio-pharmaceutical Corporation Ltd.(HBPCL), Parel, Mumbai Government of Maharashtra Undertaking invites Expression of Interest (EOI) from the eligible Organizations, Bio-Pharma Companies, Vaccine Manufacturers for Commercial Manufacturing using **‘Lyophilized strains of Diphtheria, Pertussis and Tetanus’** available with HBPCL for Joint Venture / Strategic Partnership of DPT,TT or Pentavalent vaccine useful in vaccine production⁽¹⁾

The EOI document containing the details of qualification criteria, submission details, brief objective & scope of work and evaluation criteria etc. can be downloaded from website (www.mahatenders.gov.in or www.vaccinehaffkine.com)

Schedule for the Proponents is as under:

EOI Document Number	HBPCL/EOI/001/DPT/2026
Date of Publication	Date: 18/02/2026 (11:00 am)
Last date of submission	Date: 04/03/2026 (3:00 pm)

Note:

Interested parties may please send their technical proposal in a sealed envelope to the following address:

Managing Director
Haffkine Bio pharmaceutical Corporation Ltd.
(A Govt. of Maharashtra Undertaking)
Regd. office- Acharya Donde Marg, Parel, Mumbai-400012
Phone: +91-22-24129320-22/24147564
E-Mail-md@vaccinehaffkine.com, mm@vaccinehaffkine.com
Contact person - Mr. Umesh Pawar, (+91-9222333707)
Mr. Kishor Vispute, (+91-9004684730)

EOI Document No. HBPCL/EOI/001/DPT/2026 along with the title of the EOI as **“EOI for Joint Venture / Strategic Partnership for DPT vaccine”** in **Bold** and complete address as above must be clearly mentioned on the sealed envelope.

HBPCL reserves the right to cancel this EOI and/or invite afresh with or without amendments, without liability or any obligation for such EOI and without assigning any reason. Information provided at this stage is indicative and HBPCL reserves the right to amend/add any further details in the EOI, as may be desired by the Competent Authority of HBPCL and duly notified on its website.

Background

Haffkine Bio-Pharmaceutical Corporation Ltd. (HBPCL), a Government of Maharashtra Undertaking, was previously engaged in the manufacture of DPT (Diphtheria, Pertussis, Tetanus) vaccine. The live strains of the vaccine components, namely *Corynebacterium diphtheriae* (Diphtheria), *Bordetella pertussis* (Pertussis), and *Clostridium tetani* (Tetanus), are presently held in the custody of the HBPCL.

HBPCL hereby invites Expression of Interest (EOI) from reputed, duly licensed, and technically qualified vaccine manufacturers and/or recognized research institutions having a sound financial background, for entering into a royalty-based Joint Venture / Strategic Partnership for utilization of the aforesaid DPT vaccine live strains (production/sales), through a transparent and competitive process.

The selected entity/entities shall be permitted to utilize the DPT strains for vaccine manufacturing and/or related research activities under mutually agreed terms.

Proposed Business Model

The proposed arrangement shall be on a royalty-based model. The detailed commercial and contractual terms, including royalty structure, tenure, and compliance requirements, shall be finalized with the selected entity/entities at a subsequent stage.

2. Objective

The eligible Organizations, Bio-Pharma Companies, Vaccine Manufacturers for Commercial Manufacturing using **'Lyophilized strains of Diphtheria, Pertussis and Tetanus'** available with HBPCL for Joint Venture / Strategic Partnership of DPT,TT or Pentavalent vaccine useful in vaccine production⁽¹⁾

3. Scope of Work

- i. HBPCL is willing to collaborate with eligible organizations, companies, and manufacturers for Joint Venture / Strategic Partnership of DPT lyophilized strains⁽¹⁾
- ii. The selected party would be granted rights to undertake further development, manufacture, sell, and commercialize the Technology/Product (Details of technology/Product) or undertake further R&D and commercialize the end product(s) /technology.
- iii. An Agreement (in case of Joint Venture / Strategic Partnership) following EOI is proposed to be executed on a "Non-Exclusive" basis with single/multiple companies to enable wider outreach of ⁽¹⁾.

Role of HBPCL:

HBPCL will provide the lyophilized strains of *Corynebacterium diphtheriae* (Diphtheria), *Bordetella pertussis* (Pertussis), and *Clostridium tetani* (Tetanus), Which are presently in the custody of HBPCL.

Role of Company / Vaccine Manufacturer (Selected Party)

- i. The Selected Party shall have valid provisions to provide all necessary infrastructure/ material/ manpower required for product development/ validation/ scale-up.
- ii. The Selected Party shall have provisions to undertake the scale-up as required, manufacturing and commercialization of (1),
- iii. The Selected Party agrees to share the technical data with HBPCL and participate in all discussions in a professional and mutually agreed-upon manner.
- iv. The Selected Party to allow authorized personnel/scientist/team of HBPCL to visit the designated lab/ production facility as and when required, as envisaged under this EOI and subsequent Agreement.
- v. The Selected Party shall be responsible for obtaining all the regulatory approvals required for commercialization or starting from R&D for product development to its commercialization.

4. Intellectual Property Rights

It is submitted that in case of transfer of DPT lyophilized culture, HBPCL is the sole owner of the said strains, including any underlying Intellectual Property(ies) and commercialization rights.

Intellectual Property (IP) shall mean patents, rights to inventions, copyright and related rights, moral rights, rights in designs, rights in trademarks, rights to preserve the confidentiality of information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply for and be granted), divisional, continuations, continuations-in-part, reissues, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world regarding subject matter disclosed in Licensed patents.

HBPCL legally possess the rights and authority to retain full or part of the 'Bacterial culture' by itself or to assign at its discretion full or part of the Technology including any patent(s) or intellectual property rights(s) or the invention(s), and/or HBPCL is lawfully entitled to enter into any form of non-

exclusive License Agreements with selected companies including transfer of the Technology or Material through suitable Agreement(s).

In case of collaboration between HBPCCL and the Selected Company for the Joint Venture / Strategic Partnership shall always remain the sole and exclusive property of DPT strains with HBPCCL. Any IP, if generated during the course of collaboration, including any improvement thereof, shall be jointly owned by HBPCCL and the Selected Company. All such provisions related to intellectual property rights shall be governed by HBPCCL management Policy, as revised and approved by the Competent Authority.

5. Process involved in Joint Venture / Strategic Partnership

Interested Companies/Manufacturers are invited to join hands with HBPCCL for Joint Venture / Strategic Partnership. Under this EOI, the manufacturers/companies who are responsive and fulfilling all the technical need will be shortlisted based on their Proposal as per capabilities. Qualified Parties will only be contacted for execution of MOA/MOU/Agreement for Joint Venture / Strategic Partnership etc. Subsequent to the execution of the Agreement such companies/manufacturers shall be responsible to pay the Royalty @ minimum 5% on Net sales/production of DPT group of vaccine like DPT, TT, DT, Quadrivalent, Pentavalent, Hexavalent or any related production of vaccines (Drug Substance & Drug Formulation) using the HBPCCL strain whereas applicable.

6. Security Deposit:-

The applicant shall propose the Security Deposit amount in its financial proposal, commensurate with:

- 6.1 Proposed annual production capacity,
- 6.2 Estimated turnover from DPT vaccine,
- 6.3 Royalty commitment to HBPCCL,
- 6.4 Scale of operations and market coverage.

- The applicant shall clearly specify the offered Security Deposit amount in its Financial Proposal.
- The Security Deposit offered by the applicant shall constitute a major evaluation parameter and shall carry significant weightage in the overall assessment of proposals.
- The offer quoting the highest and most commercially advantageous Security Deposit, along with compliance to technical and eligibility criteria, shall be considered favorably.
- The Security Deposit shall act as a financial assurance towards performance of contractual obligations under the proposed Joint Venture / Strategic Business Tie-up arrangement.
- The final Security Deposit amount shall be subject to approval and shall be incorporated in the definitive Agreement to be executed between HBPCCL and the selected partner.
- The Security Deposit **shall be refundable**, subject to compliance with

contractual obligations, and shall remain valid for the duration of the Agreement.

7. Details of documents to be furnished

Proponents are requested to go through all pre-qualification requirements, scope of work for execution & requirements with respect to technical capabilities for submission of interest, subject for verification by HBPCL.

Documents to be furnished are as follows:

- i. Declaration - Expression of Interest (Format – 1)
- ii. Authorization Letter (Format – 2)
- iii. Undertaking with regard to Blacklisting (Format-3)
- iv. Undertaking with regard to Non-Conviction (Format – 4)
- v. EOI document with each page duly stamped and signed by the Authorized signatory.
- vi. Undertaking with regard to Laboratory Facility (Format – 5)
- vii. Production Capacity undertaking (Format-6)

HBPCL reserves all the rights to call for any clarifications confined in the broad scope, wherever such a clarification becomes necessary for proper judgment in evaluation.

8. Rejection Criteria

The application is liable to be rejected if:

- i. The proposal is not submitted as per the requirements indicated in the EOI.
- ii. Not in the prescribed format.
- iii. Not properly stamped and signed.
- iv. Received after the expiry of due date and time.
- v. All relevant supporting documents are not furnished with the Pre-Qualification Criteria (PQC).
- vi. The proposal shall be substantially responsive without any material deviation, failing which the proposal shall be summarily rejected.
- vii. Applications not fulfilling the terms of the document will be summarily rejected.
- viii. Any other non-compliance.

9. Evaluation Methodology

Screening of EOI's shall be carried out as per Pre-Qualification criteria mentioned in the EOI document and based on verification of documents submitted.

10. Pre-Qualification Criteria (PQC)

The following will be the minimum Pre-Qualification Criteria (PQC). Responses not meeting the minimum PQC will be summarily rejected and will not be evaluated further:

Sl. No.	Pre-Qualification Criteria (General)	Supporting copy of documents required (All documents must be self-attested by the authorized person of the proponent)
General Criteria		
1	The proponent shall be a legal entity, registered as Institution/Company/ LLP/ Society/ partnership firm/ proprietorship firm under respective acts in India	Registration of firm/ organization/Company Incorporation Certificate from Registrar of Companies (ROC) /Partnership deed etc. whichever is applicable
2	The proponent must be registered in India with taxation and other administrative authorities.	GST Registration or GST exemption certificate/ PAN Card
3	The proponent should have proven prior experience of manufacturing and/or R&D with manufacturing during the last three years, either in-house or through agreed collaboration and must have marketed same/similar products in the past with a good track record.	Research paper/Pamphlet / brochure of the product/DCGI License for existing product. Supporting documents for collaboration, if any.
4	The proponent has to be profitable and should not have incurred overall loss in past three (3) years. (applicable on commercial firms/organizations only)	Net worth Certificate from the Chartered Accountant of the Organization/ Audited Balance sheets for last three financial years and Income Tax returns.
5	The proponent should have good track record and currently not black-listed/ barred by any Central / State Government / Public Sector Undertaking, Govt. of India, (applicable on commercial firms/organizations only).	Undertaking on the Letter Head of the Proponent duly signed & Stamped by Authorized Signatory (As per Format – 3).
6	The proponent should have a Manufacturing unit.	Registration copies/ factory license/ DSIR certificate, if have any.
7	The proponent and its promoters should not have been convicted for any offence globally by any competent court or judicial body during the past 3 years.	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory (As per Format – 4)
8	GMP/ quality certification (ISO or approved Competent Certification) of manufacturing facility and GLP/	Copies of Certificates

	necessary certifications for R & D	
Specific Criteria (Based on the nature of the Proposal)		
9.	The proponent should have functional laboratory to carryout R&D for the product development	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory (As per Format – 5)
10.	Capacity to produce at least.....(quantity) per week	Undertaking (As per Format – 6)

11. Disclaimer

- i. HBPCL shall not be responsible for any late receipt of applications for any reasons whatsoever.
- ii. HBPCL reserves the rights to cancel the call for EOI without assigning any reasons thereof.
- iii. HBPCL may relax or waive any of the conditions stipulated in this document as deemed necessary in the best interest of the HBPCL without assigning any reasons thereof.
- iv. To include any other item in the Scope of work at any time after consultation with proponents or otherwise.

12. Arbitration

That any dispute and/ or any part of the dispute which couldn't be resolved through mutual consultation, the same shall be referred to the sole arbitrator as per the Arbitration & Conciliation Act, 1996 and any amendment thereafter. The Venue and Seat of the arbitration proceedings shall be Mumbai and the courts at Mumbai will have exclusive jurisdiction.

Format-1

Expression of Interest

(To be submitted on Company's Letter Head)

To,
To,
The Managing Director,
Haffkine Bio-Pharmaceutical Corp. Ltd.
Acharya Donde Marg, Parel
Mumbai – 400 012

Subject: Submission of Expression of Interest (EOI) for '**Lyophilized strains of Diphtheria, Pertussis and Tetanus**' available with HBPCL for Joint Venture / Strategic Partnership of DPT,TT or Pentavalent Vaccine useful in vaccine production.

Ref: ADVT NO. HBPCL/EOI/001/DPT/2026/ dated 18/02/2026

Sir,

The undersigned having read and examined in detail all the EOI documents pertaining to your transfer of technology, and do hereby express the interest to undertake the Research &Development/Joint Venture/ Strategic Partnership for the product as mentioned in the EOI document. The details of the Company and contact person are given below:

Name of the Proponent	
Address	
Name, designation & address of the person (to whom all communications shall be made)	
Telephone No. (with STD code)	
Mobile No. of the contact person	
Email ID of the contact person	

The following documents are enclosed:

Sl. No.	Documents required	Type of document attached	Page No.
1	Company Incorporation Certificate from ROC/Partnership deed etc.		

2	GST Registration or GST exemption certificate/ PAN Card.		
3	DCGI/CDSCO license for the existing products available in the market		
4	Certificate from the Chartered Accountant of the Organization/ Audited Balance sheets for last three financial years, Income Tax return.		
5	Proof of a registered office and a Manufacturing Unit in India/Globally. Including Regulatory/DSIR certificate		
6	GMP / GLC and ISO Certification. Registration copies of both		
7	Authorization Letter	As per Format – 2	
8	Undertaking on the Letter Head of the Proponent duly signed & Stamped by Authorized Signatory	As per Format – 3	
9	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory	As per Format – 4	
10	MSME Certificate,if applicable		
11	Business Plan	A brief concept note on planning & execution, production, marketing etc. (not more than 5 pages)	

I/we hereby declare that my/our EOI is made in good faith and the information contained is true and correct to the best of my/our knowledge and belief.

Thanking you,

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-2

Authorization Letter

(To be submitted on Company's Letter Head)

To,
The Managing Director,
Haffkine Bio-Pharmaceutical Corp. Ltd.
Acharya Donde Marg, Parel
Mumbai – 400 012

Subject: Letter for Authorized Signatory

Ref: ADVT NO. HBPCL/EOI/001/DPT/2026/ dated 18/02/2026

Sir,

This has reference to your above-mentioned Expression of Interest (EOI) for **'Lyophilized strains of Diphtheria, Pertussis and Tetanus'** available with HBPCL for Joint Venture / Strategic Partnership of DPT, TT or Pentavalent vaccine useful in vaccine production

Mr./Ms./Mrs./Dr.....is hereby authorized to submit the EOI documents and participate in the processing on behalf of M/s..... (Company Name), who's signature is below.

(Specimen Signature of Representative)

Date:

Place:

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Format-3

Undertaking with regard to blacklisting

(To be submitted on Company's Letter Head)

To,
The Managing Director,
Haffkine Bio-Pharmaceutical Corp. Ltd.
Acharya Donde Marg, Parel
Mumbai – 400 012

Subject: Undertaking regarding Blacklisting / Non-Debarment.

Ref:ADVT NO. HBPCL/EOI/001/DPT/2026/ dated 18/02/2026

Sir,

It is hereby confirmed and declared that M/s..... (Company Name) currently has not been blacklisted / debarred by any Government Department / Public Sector Undertaking / or any other company for which works/assignments/services have been executed / undertaken.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-4

Undertaking with regard to Non-Conviction

(To be submitted on Company's Letter Head)

To,
The Managing Director,
Haffkine Bio-Pharmaceutical Corp. Ltd.
Acharya Donde Marg, Parel
Mumbai – 400 012

Subject: Undertaking regarding Non-Conviction.

Ref: ADVT NO. HBPCL/EOI/001/DPT/2026/ dated 18/02/2026

Sir,

It is hereby confirmed and declared that M/s.....(Company Name) and owner of the firm / board of directors, have not been convicted for any offence in India by any competent court or judicial body during the past 3 years.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-5

Undertaking with regard to laboratory facility

(To be submitted on Company's Letter Head)

To,
The Managing Director,
Haffkine Bio-Pharmaceutical Corp. Ltd.
Acharya Donde Marg, Parel
Mumbai – 400 012

Subject: Undertaking regarding laboratory infrastructure.

Ref: ADVT NO. HBPCL/EOI/001/DPT/2026/ dated 18/02/2026

Sir,

It is hereby confirmed and declared that M/s..... (Company Name) do have

- i. Adequate laboratory infrastructure (equipped laboratory facility).
Please tick BSL-2/BSL-3/ABSL-3/GMP/GLP/ Other* (if other please specify).

- ii. Adequate No. of experienced staff/skilled manpower to undertake manufacture/ research/ commercialization of (Product details).

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-6

Undertaking with regard to production capacity

(To be submitted on Company's Letter Head)

To,
The Managing Director,
Haffkine Bio-Pharmaceutical Corp. Ltd.
Acharya Donde Marg, Parel
Mumbai – 400 012

Subject: Undertaking with regard to production capacity.

Ref: ADVT NO. HBPCL/EOI/001/DPT/2026/ dated 18/02/2026

Sir,

It is hereby confirmed and declared that M/s..... does have the capacity in all mean (including infrastructure, fund, material, staff etc.) for manufacturing of (Name of Technology/ Product), minimum(mention the quantity per week/per month).

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place: